Skip to content

Study · Randomized controlled trial · n = 18 · 2010

2 results

Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder.

Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, Stout JC, Nathan PJ

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology18 Aug 2010Cited by 380 (Europe PMC)

PMID20720535 (opens in a new tab)PMCIDPMC3055328 (opens in a new tab)DOI10.1038/npp.2010.123 (opens in a new tab)PepBankPUB-20720535
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with generalized social anxiety disorder, intranasal oxytocin attenuated the heightened amygdala reactivity to fearful faces seen during placebo.

    In plain wordsIn adults with social anxiety disorder, nose-spray oxytocin reduced the raised brain-scan response to fearful faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseAmygdala reactivity to fearful faces in generalized social anxiety disorder
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU (40.32 μg) · intranasal · single acute doseAs given in this study (human).

    Source sentences

    Summary
    attenuated the heightened amygdala reactivity to fearful faces in the GSAD group, such that the hyperactivity observed during the placebo session was no longer evident following OXT (ie, normalization)
    1 context sentence
    Summary · context
    In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy control adults, intranasal oxytocin had no effect on amygdala activity to emotional faces.

    In plain wordsIn healthy adults, nose-spray oxytocin did not change the brain-scan response to emotional faces.

    Peptide
    Oxytocin
    Outcome
    No significant changeAmygdala activity to emotional faces in healthy controls
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    24 IU (40.32 μg) · intranasal · single acute doseAs given in this study (human).

    Source sentences

    Summary
    OXT had no effect on amygdala activity to emotional faces in the CON group
    1 context sentence
    Summary · context
    In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.